Loading clinical trials...

An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGPHASE2

An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer

NCT07061210•Fudan University

View on ClinicalTrials.gov

Summary

To evaluate the safety and efficacy of HRS-2189 combined with Adebrelimab and BP102 in the treatment of metastatic colorectal cancer

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1.18-75 years; 2.Histological confirmed metastatic colorectal cancer; 3.ECOG PS 0-1; 4.At least one measurable lesion (according to RECIST1.1); 5.Patients voluntarily enroll in the study.

Exclusion Criteria

•1. The patient has had other malignant tumors within 5 years (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);
•2. Symptomatic brain or meningeal metastases (except for those whose BMS disease is stable for at least 4 weeks);
•3. Allergy to the study drug or any of its excipients;
•4. Prior treatments or medications received before the first study treatment as follows:
•1. Major surgery within 28 days before treatment (tissue biopsy for diagnostic purposes is allowed).
•2. Use of immunosuppressive drugs within 7 days before treatment, excluding intranasal and inhaled corticosteroids or physiological doses of systemic steroids (i.e., no more than 10 mg/day of prednisone or an equivalent dose of other corticosteroids);
•3. Administration of immunomodulatory drugs (such as thymosin, interferon, interleukin) within 3 weeks before treatment;
•4. Vaccination with live attenuated vaccines within 28 days before treatment;
•5. Other systemic anti-tumor therapies within 28 days before treatment;
•5. Any active autoimmune disease or a history of autoimmune disease with an anticipated recurrence;
+7 more criteria

Key Dates

Start Date

July 1, 2025

Primary Completion Date

October 1, 2026

Completion Date

January 1, 2027

Last Updated

July 11, 2025

Enrollment

ESTIMATED participants

Conditions

Colorectal Cancer Metastatic

Interventions

HRS-2189

DRUG

Adebrelimab

DRUG

BP102

DRUG

A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer

NCT05759728

Colorectal Cancer Metastatic

View study

RECRUITINGEARLY_PHASE1

COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer

NCT07328087

Colorectal Cancer MetastaticColorectal Cancer Stage III+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 11, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer

Inclusion Criteria

Exclusion Criteria

A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer

COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer

STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer

A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.

A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis